JPM vs KMPR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
KMPR presents as a classic value trap; while the Graham Number ($48.53) and P/B ratio (0.74) suggest deep value, the fundamental health is deteriorating. The Piotroski F-Score of 4/9 indicates only stable health, which is overshadowed by a catastrophic earnings trend featuring 0 beats in the last 4 quarters and a -57.11% average surprise. With YoY EPS growth collapsing by 83.4% and a bearish technical trend (0/100), the low valuation is a reflection of declining business quality rather than a market mispricing.
Compare Another Pair
Related Comparisons
JPM vs KMPR: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Kemper Corporation (KMPR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.